scholarly article | Q13442814 |
P2093 | author name string | van Marwijk Kooy M | |
Akkerman JW | |||
Moes M | |||
van Prooijen HC | |||
Bosma-Stants I | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | randomized experiment | Q1231081 |
P304 | page(s) | 201-205 | |
P577 | publication date | 1991-01-01 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial | |
P2283 | uses | randomized experiment | Q1231081 |
P478 | volume | 77 |
Q24186913 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
Q90708330 | Analysis of Plasma Products for Cellular Contaminants: Comparing Standard Preparation Methods |
Q71787415 | Autologous platelet transfusion in alloimmunized patients with acute leukemia |
Q46689029 | C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants. |
Q42147720 | Comparative Study of Predeposit and Bedside Leucodepletion Filters |
Q24187751 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
Q33412070 | Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets |
Q24186359 | Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
Q33432719 | Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions |
Q35924467 | Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products |
Q26771857 | Leucoreduction of blood components: an effective way to increase blood safety? |
Q33760699 | Leukoreduced blood components: Advantages and strategies for its implementation in developing countries |
Q37303143 | Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response |
Q30539028 | Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants |
Q28749508 | Management of allosensitized cardiac transplant candidates |
Q90627632 | Pathogen reduction with riboflavin and ultraviolet light induces a quasi-apoptotic state in blood leukocytes |
Q33345178 | Platelet therapy |
Q34708937 | Platelet transfusions: Impact on hemostasis, thrombosis, inflammation and clinical outcomes |
Q38794017 | Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood. |
Q36746594 | The HLA system: genetics, immunology, clinical testing, and clinical implications |
Q36766478 | The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation |
Q41979922 | Time Dependent Release of Interleukin-8 and Tumor Necrosis Factor-α in Platelet Concentrate |
Search more.